Ludovic Helfgott/LinkedIn
Nov 15, 2025, 15:45
Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
Ludovic Helfgott, Executive Vice President, Product and Portfolio Strategy at Novo Nordisk, shared a post on LinkedIn:
“New paper in The Lancet Group today. Researchers have analysed Novo Nordisk product data in obesity and cardiovascular disease and the results suggest that a reduction of major adverse cardiovascular events in people with overweight or obesity is independent of baseline weight and weight loss.
These findings again support our strategy to reduce the risk of cardiovascular events for the hundreds of millions of people living with overweight or obesity and cardiovascular disease and promote their long-term health.”
Stay updated with Hemostasis Today.
-
Sep 6, 2026, 18:17Aryabhatta Sadhu: Irradiation of Blood Components – From Clinical Indication to Laboratory Release
-
Sep 6, 2026, 18:15Ashenafi Tazebew Amare: A Year of Progress, Transformation and Renewed Commitment
-
Sep 6, 2026, 18:13Emilio Osorio: Can Anticoagulation Be Safely Discontinued After Surgical Left Atrial Appendage Occlusion?
-
Sep 6, 2026, 18:11Razan Alolyani: Our Research on Anticoagulation After Acute Ischemic Stroke Receives 2nd Place
-
Sep 6, 2026, 18:10Chayakrit Krittanawong: Have You Heard of Blood Clots in the Legs?
-
Sep 6, 2026, 18:08Trilok Chand: Microplastics Found in Human Testes and Blood Clots
-
Sep 6, 2026, 18:07Sarah Moharem Elgamal: Cardiovascular Imaging Beyond Anatomy Toward Earlier Risk Prediction
-
Sep 6, 2026, 16:41Christina (Tina) P.: APS – How it Happens in Your Blood, the Warning Signs, and What to Do about It
-
Sep 6, 2026, 16:33Jose Angel Nicolas Avila: How Tissue Mitochondrial Activity Dictates Macrophage Pool Size